Breaking the Bottleneck of Traditional Single-Payload ADCs: HK815,...

Ajout d’un nouvel article Health

2026-04-21 07:46:24

Breaking the Bottleneck of Traditional Single-Payload ADCs: HK815, a TROP2 Dual-Payload ADC by HKBio, Leads the Next Generation of Cancer Therapy

Antibody-drug conjugates (ADCs) have become a major direction in precision oncology and, in recent years, have emerged as another high-growth therapeutic class following PD-1 inhibitors. From Trodelvy to Datopotamab Deruxtecan, multiple TROP2-targeting ADCs have demonstrated promising efficacy in solid tumors such as breast cancer and lung cancer. However, with deeper clinical...

0 Commentaires 0 Parts 179 Vue 0 Aperçu

Connect Freelancing Platform